RC110 was and is very successful, but it is limited for a number of reasons when used outside of AML. Race before my time was focused purely on AML so this wasn't too much of a problem, but now we know bisantrene has much more potential, a new formulation was needed and developed. Developing the new Rc220 formulation was not easy.
We have put a lot of effort in to identifying exactly the market we want to target and what data we need to generate to show any serious partner or investor to get their interest. It is all too easy in biotech to get excited by all the science and lose track of the commercial aspects. While I am a scientist and love the science, I am an investor and I am at Race to make an excellent return for all shareholders.
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-152
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.025(1.76%) |
Mkt cap ! $242.0M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $107.5K | 75.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12711 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 1250 | 1 |
View Market Depth
| Last trade - 12.34pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |